BIOMEDE : Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication

Male or<br/>FemaleGender Male or
Female

RecruitingStatus Recruiting

Systemic<br/>Therapy TrialTypeSystemic
Therapy Trial

TwoPhase Two

0-25Age 0-25

Brain and Spinal<br/>CancersCancer LocationBrain and Spinal
Cancers

Systemic therapy | Brain and spinal cordGlioma

Trial Overview Read MoreRead more

This phase II trial is testing three oral drugs (Erlotinib, Everolimus and Dasatinib) as a possible treatment for Diffuse Intrinsic Pontine Glioma (DIPG).
 

This trial is treating patients with Diffuse Intrinsic Pontine Glioma (DIPG).

This is a systemic therapy trial.

You may be able to join this trial if:

  • You have been diagnosed with cancer, but have not received any treatment.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have been diagnosed with a prior or secondary type of cancer.
  • You have had certain treatments, surgical procedures or drugs.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication

Cooperative Group

Innovative Therapies For Children with Cancer Consortium

Other Non-Commercial Sponsor

Gustave Roussy, Cancer Campus, Grand Paris

Summary

Participants in this study will be allocated to a treatment that specifically targets a biological abnormality identified via a biopsy. The possible treatment groups are as follows; (1)If the tumor overexpresses EGFR without PTEN loss of expression, patients may receive erlotinib or dasatinib allocated by randomization; (2) If the tumor shows loss of PTEN expression without EGFR overexpression, patients may receive everolimus or dasatinib allocated by randomisation; (3) If the tumor shows both EGFR overexpression and loss of PTEN expression, patients may receive erlotinib, everolimus or dasatinib by randomisation; (4) If the tumor shows neither EGFR overexpression nor loss of PTEN expression (a very rare situation in our experience), patients will receive dasatinib; (5) If the biopsy assessment is not contributive, the treatment will be allocated by randomisation between erlotinib, everolimus and dasatinib.

Recruiting Hospitals Read MoreRead more

Monash Children's Cancer Centre
Clayton
Ms Irina Arzhintar
Irina.Arzhintar@monashhealth.org
(03) 8572 3490

Royal Childrens Hospital
Parkville
Ms Kahlia Fox
kahlia.fox@mcri.edu.au
(03) 9345 6214

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.

Next